Jeffrey Harris, MD
Family Medicine · Newville, PANPI 1689649626
Payments from drug & device makers
Across 166 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$361
- AbbVie$315
- AstraZeneca$310
- GSK$242
- Merck$166
- Pfizer$156
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,901100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $361 |
| AbbVie(2 entities) | 14 | $315 |
| AstraZeneca | 20 | $310 |
| GSK | 13 | $242 |
| Merck | 9 | $166 |
| Pfizer | 11 | $156 |
| Boehringer Ingelheim | 10 | $145 |
| Amgen | 9 | $145 |
| Lilly USA, LLC | 9 | $141 |
| Sanofi Pasteur Inc. | 5 | $110 |
| Novartis | 5 | $82 |
| Johnson & Johnson | 5 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Amarin Pharma, Inc. | 4 | $65 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| Abbott | 2 | $45 |
| Exact Sciences | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Mylan Specialty L.p. | 2 | $42 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Indivior Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Cequr Corporation | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $4 |
How this compares
$2,907 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 243 | $227,833 |
| EliquisApixaban | 107 | $115,859 |
| OzempicSemaglutide | 38 | $64,104 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $52,030 |
| FarxigaDapagliflozin Propanediol | 32 | $50,075 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $37,296 |
| MounjaroTirzepatide | 35 | $35,740 |
| TradjentaLinagliptin | 23 | $31,939 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $28,226 |
| XareltoRivaroxaban | 15 | $24,203 |
| RybelsusSemaglutide | 16 | $21,433 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 93 | $20,743 |
| ProliaDenosumab | 12 | $20,194 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $19,123 |
| TrulicityDulaglutide | 14 | $18,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $145 | $259,772266 claims |
| PfizerEliquis | $156 | $115,859107 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $242 | $106,630239 claims |
| Novo NordiskOzempic, Rybelsus | $361 | $85,53754 claims |
| Lilly USA, LLCMounjaro, Trulicity | $141 | $54,46349 claims |
| AstraZenecaFarxiga | $310 | $50,07532 claims |
| Johnson & JohnsonXarelto | $77 | $24,20315 claims |
| AmgenProlia | $145 | $20,19412 claims |
| MerckJanuvia | $166 | $17,94918 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $8,59712 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $29 | $3,27511 claims |
| AbbVieSynthroid | $315 | $1,95335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Newville
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.